-
Mashup Score: 0
The Y chromosome histone demethylase gene, KDM5D, drives sex differences in colorectal cancer (CRC).
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Secondary Bladder Cancers Following Low-Dose Brachytherapy for Prostate Cancer - Expert Commentary - 11 month(s) ago
effect of radiation on clinical parameters among patients with secondary bladder cancer, muscle-invasive bladder cancer (MIBC), radiation therapy, bladder cancer, urothelial carcinoma, Low-Dose Brachytherapy, brachytherapy for prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Secondary #BladderCancers following low-dose brachytherapy for #ProstateCancer. #ExpertCommentary. @FaltasLab @WCMEnglanderIPM discusses work by Chin et al. in @UrolOncol > https://t.co/BUJCxjYhgB https://t.co/07uTsCGcYx
-
-
Mashup Score: 1Secondary Bladder Cancers Following Low-Dose Brachytherapy for Prostate Cancer - Expert Commentary - 1 year(s) ago
effect of radiation on clinical parameters among patients with secondary bladder cancer, muscle-invasive bladder cancer (MIBC), radiation therapy, bladder cancer, urothelial carcinoma, Low-Dose Brachytherapy, brachytherapy for prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Secondary #BladderCancers following low-dose brachytherapy for #ProstateCancer. #ExpertCommentary. @FaltasLab @WCMEnglanderIPM discusses work by Chin et al. in @UrolOncol > https://t.co/BUJCxjYhgB https://t.co/qhd7Vjcah8
-
-
Mashup Score: 0Secondary Bladder Cancers Following Low-Dose Brachytherapy for Prostate Cancer - Expert Commentary - 1 year(s) ago
effect of radiation on clinical parameters among patients with secondary bladder cancer, muscle-invasive bladder cancer (MIBC), radiation therapy, bladder cancer, urothelial carcinoma, Low-Dose Brachytherapy, brachytherapy for prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Secondary #BladderCancers following low-dose brachytherapy for #ProstateCancer. #ExpertCommentary. @FaltasLab @WCMEnglanderIPM discusses work by Chin et al. in @UrolOncol > https://t.co/BUJCxjYhgB https://t.co/BOUiRleQBg
-
-
Mashup Score: 9
ESMO 2022 post-hoc aggregate analysis of the BC2001 and BCON trials aimed at assessing the effect of tumor hypoxia on radiotherapy fractionation schedules, hypoxic MIBC has a poor prognosis
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Hypoxic #BladderCancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials. Presentation by Tim Smith, MD, PhD @aberdeenuni. #ESMO22 coverage by @WallisCJD @UofT > https://t.co/V2jO1aoIcN @myESMO https://t.co/dQyhnk5tnx
-
-
Mashup Score: 0Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling - 3 year(s) ago
Basal and luminal subtypes of invasive bladder tumors have significant prognostic and predictive impacts for patients. However, it remains unclear whether tumor subtype commitment occurs in noninvasive urothelial lesions or in carcinoma in situ (CIS) and which gene pathways are important for bladder tumor progression. To understand the timing of this commitment, we used gene expression and…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
When do non-invasive urothelial lesions and/or carcinoma in situ become committed to #BladderCancers? Wullweber et al present a model exploring this question. @MarkusEckstein3 https://t.co/t9TLSoa9jz https://t.co/V53Pbr9b4D
-
-
Mashup Score: 4Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling - 3 year(s) ago
Basal and luminal subtypes of invasive bladder tumors have significant prognostic and predictive impacts for patients. However, it remains unclear whether tumor subtype commitment occurs in non-invasive urothelial lesions or in carcinoma in situ (CIS) and which gene pathways are important for bladder tumor progression. To understand the timing of this commitment, we used gene expression and…
Source: Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
When do non-invasive urothelial lesions and/or carcinoma in situ become committed to #BladderCancers? Wullweber et al present a model exploring this question. @MarkusEckstein3 https://t.co/LYeF44FBys https://t.co/MKtRvB3K92
-
-
Mashup Score: 0Molecular Subtypes of T1 Bladder Cancers - Expert Commentary - 3 year(s) ago
biological characteristics determining clinical outcomes of T1 bladder cancers, molecular characteristics of T1 non muscle-invasive bladder cancers, luminal papillary T1 tumors, biology of T1 nonmuscle-invasive bladder cancers.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Molecular subtypes of T1 #BladderCancers. #ExpertCommentary by @FaltasLab @EngIPM of Robertson et al. article published in @EUplatinum. #ReadNow on UroToday > https://t.co/LH6Yo7ueHy @cs_groen @LDyrskjot @JoshMeeks @WeillCornell @cornellGUcancer https://t.co/wbyyFXx5Lx
-
-
Mashup Score: 1Molecular Subtypes of T1 Bladder Cancers - Expert Commentary - 3 year(s) ago
biological characteristics determining clinical outcomes of T1 bladder cancers, molecular characteristics of T1 non muscle-invasive bladder cancers, luminal papillary T1 tumors, biology of T1 nonmuscle-invasive bladder cancers.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Molecular subtypes of T1 #BladderCancers. #ExpertCommentary by @FaltasLab @EngIPM of Robertson et al. article published in @EUplatinum. #ReadNow on UroToday > https://t.co/LH6Yo7ueHy @cs_groen @LDyrskjot @JoshMeeks @WeillCornell @cornellGUcancer https://t.co/YnVGjWCw4v
-
-
Mashup Score: 0Molecular Subtypes of T1 Bladder Cancers - Expert Commentary - 4 year(s) ago
biological characteristics determining clinical outcomes of T1 bladder cancers, molecular characteristics of T1 non muscle-invasive bladder cancers, luminal papillary T1 tumors, biology of T1 nonmuscle-invasive bladder cancers.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Molecular subtypes of T1 #BladderCancers. #ExpertCommentary by @FaltasLab @EngIPM of Robertson et al. article published in @EUplatinum. #ReadNow on UroToday > https://t.co/LH6Yo7ueHy @cs_groen @LDyrskjot @JoshMeeks @WeillCornell @cornellGUcancer https://t.co/sMBTjaNiwf
-
This week's #ResearchWatch: Two papers that investigate the role of loss of the Y chromosome in #colorectal & #bladdercancers, summarizing the work of @JiexiLiPhD, @RonDePinho, @Dan_Theodorescu et al. https://t.co/nMbDyGpH96 https://t.co/wr9KMQiO2L @MDAndersonNews @CedarsSinaiMed https://t.co/Oo6SRX9Vfv